Please sign in to follow a disease.
Celgene
Clinical trials sponsored by Celgene, explained in plain language.
A biopharmaceutical company focused on cancer and inflammatory diseases, now part of Bristol-Myers Squibb.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for myeloma: phase 3 trial launches for mezigdomide combo Results expected Jan 2027 (estimated)
- First human study of BMS-986368 begins in healthy chinese volunteers Results expected Feb 2027 (estimated)
- New pill shows promise for Hard-to-Treat lymphoma Results expected Apr 2027 (estimated)
- New pill could loosen MS muscle stiffness Results expected May 2027 (estimated)
- New combo aims to tackle Hard-to-Treat myeloma Results expected May 2027 (estimated)